Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Palatin Technologies, Inc. (PTN)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.3000+0.0147 (+5.15%)
At close: 04:00PM EDT
0.3000 0.00 (0.00%)
After hours: 07:31PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.2853
Open0.2805
Bid0.3000 x 3000
Ask0.3050 x 1000
Day's Range0.2790 - 0.3050
52 Week Range0.2500 - 0.9600
Volume1,375,215
Avg. Volume681,337
Market Cap69.532M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PTN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Palatin Technologies, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • PR Newswire

    Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter

    Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced preliminary fourth quarter 2022 Vyleesi® product sales. Vyleesi is the first and only as-needed treatment approved by the U.S. Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

  • PR Newswire

    Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

    Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced results for its fiscal third quarter ended March 31, 2022.

  • PR Newswire

    Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock

    Palatin Technologies, Inc. ("Palatin" or the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that it has entered into a securities purchase agreement with institutional investors pursuant to which Palatin will issue and sell 8,100,000 shares of its Series B convertible redeemable preferred stock and 900,000 shares of its Series C convertible

Advertisement
Advertisement